Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open‑Label, Fixed-Sequence Trials in Healthy Subjects

BACKGROUND AND OBJECTIVES: Suvorexant is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by C...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Drug Investig
Autores principales: Wrishko, Rebecca E., McCrea, Jacqueline B., Yee, Ka Lai, Liu, Wen, Panebianco, Deborah, Mangin, Eric, Chakravarthy, Manu, Martinez-Cantarin, Maria P., Kraft, Walter K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6929321/
https://ncbi.nlm.nih.gov/pubmed/30810914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-019-00764-x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares